BR112018013853A2 - composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer - Google Patents

composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer

Info

Publication number
BR112018013853A2
BR112018013853A2 BR112018013853A BR112018013853A BR112018013853A2 BR 112018013853 A2 BR112018013853 A2 BR 112018013853A2 BR 112018013853 A BR112018013853 A BR 112018013853A BR 112018013853 A BR112018013853 A BR 112018013853A BR 112018013853 A2 BR112018013853 A2 BR 112018013853A2
Authority
BR
Brazil
Prior art keywords
compositions
methods related
cell systems
therapeutic cell
cancer indications
Prior art date
Application number
BR112018013853A
Other languages
English (en)
Inventor
Kahvejian Avak
Round John
Mata-Fink Jordi
Dowden Nathan
B Afeyan Noubar
J Deans Robert
Elloul Sivan
F Chen Tiffany
Wickham Tom
Straight Nissen Torben
Original Assignee
Rubius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubius Therapeutics Inc filed Critical Rubius Therapeutics Inc
Publication of BR112018013853A2 publication Critical patent/BR112018013853A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a invenção refere-se a composições e métodos relacionados com terapias multimodais, por exemplo, para tratar um câncer. uma terapia multimodal aqui descrita proporciona e/ou administra uma pluralidade de agentes que funcionam de uma maneira coordenada para proporcionar um benefício terapêutico a um sujeito em sua necessidade, por exemplo, um sujeito com câncer.
BR112018013853A 2016-01-11 2017-01-11 composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer BR112018013853A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277130P 2016-01-11 2016-01-11
US201662359448P 2016-07-07 2016-07-07
US201662370915P 2016-08-04 2016-08-04
US201662420973P 2016-11-11 2016-11-11
PCT/US2017/013035 WO2017123646A1 (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications

Publications (1)

Publication Number Publication Date
BR112018013853A2 true BR112018013853A2 (pt) 2018-12-18

Family

ID=57907000

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018013728A BR112018013728A2 (pt) 2016-01-11 2017-01-11 composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações imunitárias
BR112018013853A BR112018013853A2 (pt) 2016-01-11 2017-01-11 composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018013728A BR112018013728A2 (pt) 2016-01-11 2017-01-11 composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações imunitárias

Country Status (22)

Country Link
US (8) US10456421B2 (pt)
EP (3) EP3402491B1 (pt)
JP (5) JP7093302B2 (pt)
KR (2) KR20180095713A (pt)
CN (3) CN115969987A (pt)
AU (2) AU2017207736A1 (pt)
BR (2) BR112018013728A2 (pt)
CA (2) CA3009063A1 (pt)
DK (1) DK3402491T3 (pt)
ES (1) ES2907695T3 (pt)
HK (1) HK1259079A1 (pt)
HR (1) HRP20220147T1 (pt)
HU (1) HUE057660T2 (pt)
IL (2) IL259991A (pt)
LT (1) LT3402491T (pt)
MX (2) MX2018008515A (pt)
PL (1) PL3402491T3 (pt)
PT (1) PT3402491T (pt)
RS (1) RS62939B1 (pt)
SG (4) SG11201805253SA (pt)
SI (1) SI3402491T1 (pt)
WO (2) WO2017123644A1 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2764105T3 (es) 2011-10-17 2020-06-02 Massachusetts Inst Technology Administración intracelular
AU2014306423B2 (en) 2013-08-16 2019-04-18 Massachusetts Institute Of Technology Selective delivery of material to cells
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
CA2944492A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
SG11201703044PA (en) 2014-10-31 2017-05-30 Massachusetts Inst Technology Delivery of biomolecules to immune cells
CN107002089B (zh) 2014-11-14 2021-09-07 麻省理工学院 化合物和组合物向细胞中的破坏和场实现的递送
WO2016115179A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
EP3320082B1 (en) 2015-07-09 2023-05-24 Massachusetts Institute of Technology Delivery of materials to anucleate cells
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
SG11201805253SA (en) 2016-01-11 2018-07-30 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for cancer indications
EP3583202A1 (en) 2017-02-17 2019-12-25 Rubius Therapeutics, Inc. Functionalized erythroid cells
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
EP3664830A4 (en) 2017-08-07 2020-07-01 The Regents of the University of California PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS
CA3071881A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
CN111655292A (zh) * 2017-12-07 2020-09-11 旗舰先锋创新V股份有限公司 细胞生物制品及其治疗用途
US20190290686A1 (en) * 2017-12-23 2019-09-26 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
AU2019232012A1 (en) * 2018-03-08 2020-09-24 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases
WO2019226922A1 (en) * 2018-05-24 2019-11-28 Rush University Medical Center Icosl for use as a renal therapeutic
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
US20220112489A1 (en) 2019-01-18 2022-04-14 Flagship Pioneering, Inc. Trem compositions and uses thereof
WO2020172472A1 (en) * 2019-02-20 2020-08-27 Rubius Therapeutics, Inc. Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
KR20210135265A (ko) 2019-03-04 2021-11-12 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 원형 폴리리보뉴클레오티드 및 그의 약제학적 조성물
US20200299369A1 (en) * 2019-03-18 2020-09-24 Bio-Rad Abd Serotec Gmbh Antigen binding fragments conjugated to a plurality of fc isotypes and subclasses
EP3946466A2 (en) 2019-03-25 2022-02-09 Flagship Pioneering Innovations VI, LLC Compositions comprising modified circular polyribonucleotides and uses thereof
EP3963092A1 (en) * 2019-05-02 2022-03-09 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk
CN114269921A (zh) 2019-05-31 2022-04-01 旗舰创业股份有限公司 TREM组合物用以调节tRNA池的用途
WO2020252436A1 (en) 2019-06-14 2020-12-17 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
US20220305128A1 (en) 2019-06-19 2022-09-29 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
CN112195154B (zh) * 2019-07-08 2024-03-29 江苏汇智生物科技有限公司 一种基因改造表达改造型pla2r受体的细胞及其应用
WO2021046424A2 (en) 2019-09-05 2021-03-11 Hemanext Inc. Methods for the preservation of reagent red blood cells using carbon monoxide
CN114746545A (zh) * 2019-10-18 2022-07-12 西湖生物医药科技(杭州)有限公司 应用人工mhc呈递特异性癌症新抗原的工程化红细胞
AU2020379762A1 (en) 2019-11-04 2022-05-26 Flagship Pioneering, Inc. TREM compositions for con-rare codons and related uses
US20220364075A1 (en) 2019-11-04 2022-11-17 Flagship Pioneering, Inc. Methods of modifying a nucleic acid sequence
EP4096681A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Delivery of compositions comprising circular polyribonucleotides
TW202142689A (zh) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 用於轉譯之組合物及其使用方法
WO2021155177A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
WO2021158991A1 (en) * 2020-02-07 2021-08-12 The Regents Of The University Of California Methods and use for bioengineering enucleated cells
EP4153152A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing human polyclonal antibodies
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
JP2023526423A (ja) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 免疫原性組成物及びその使用
WO2021243301A2 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
JP2023527413A (ja) 2020-05-29 2023-06-28 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー Ｔｒｅｍ組成物及びそれに関連する方法
US20230233514A1 (en) 2020-06-23 2023-07-27 Flagship Pioneering, Inc. Antiviral compounds and methods of using the same
WO2022051629A1 (en) 2020-09-03 2022-03-10 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
JP2024501288A (ja) 2020-12-23 2024-01-11 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 修飾ｔｒｅｍの組成物及びその使用
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
AU2022227018A1 (en) * 2021-02-26 2023-10-05 Cytonus Therapeutics, Inc. Compositions and methods for therapeutic delivery
WO2022197548A1 (en) 2021-03-14 2022-09-22 Rubius Therapeutics, Inc. Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
TW202330916A (zh) 2021-09-17 2023-08-01 美商旗艦先鋒創新有限責任公司 用於產生環狀多核糖核苷酸之組成物和方法
WO2023064383A1 (en) * 2021-10-12 2023-04-20 Cytonus Therapeutics, Inc. Systems and methods for manufacturing of therapeutic cells
AU2022370530A1 (en) 2021-10-18 2024-05-02 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
CA3239266A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CA3238735A1 (en) 2021-11-24 2023-06-01 Jennifer A. Nelson Immunogenic compositions and their uses
WO2023122745A1 (en) 2021-12-22 2023-06-29 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023122789A1 (en) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
WO2023230549A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of tumor suppressors and oncogenes
WO2023230566A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
WO2023230573A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses
WO2023230570A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
WO2023230578A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating circulating factors
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2024102799A1 (en) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
WO2024129988A1 (en) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions and methods for delivery of therapeutic agents to bone

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6827094A (en) * 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20020151004A1 (en) * 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
WO2004087876A2 (en) * 2003-03-25 2004-10-14 Valeocyte Therapies Llc Use of red blood cells to facilitate cell activation
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
WO2007030708A2 (en) 2005-09-08 2007-03-15 Adnexus Therapeutics, Inc. Antimicrobial adzymes and uses thereof
US7462485B2 (en) 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
EP2242507B1 (en) 2008-02-13 2013-02-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
CA2778669C (en) 2009-10-27 2019-04-16 Erytech Pharma Composition to induce specific immune tolerance
JP6017422B2 (ja) * 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
AU2013203832B2 (en) 2012-03-13 2016-09-15 Celularity Inc. Modified erythrocyte precursor cells and uses thereof
CN104394884A (zh) 2012-03-21 2015-03-04 爱瑞泰克药物公司 用于治疗急性髓细胞白血病(aml)的药剂
CN103224957B (zh) 2013-04-16 2017-08-04 福建三一造血技术有限公司 体外诱导生成含L‑ASPase II的红细胞药物的方法
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
ES2901383T3 (es) 2013-05-10 2022-03-22 Whitehead Inst Biomedical Res Producción in vitro de glóbulos rojos con proteínas marcables con sortasa
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
CA2944492A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
WO2016183482A1 (en) * 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP3187190A1 (en) 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201805253SA (en) 2016-01-11 2018-07-30 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for cancer indications
US20190161730A1 (en) 2016-07-07 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
US20180153989A1 (en) * 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
EP3583202A1 (en) 2017-02-17 2019-12-25 Rubius Therapeutics, Inc. Functionalized erythroid cells
US20190062788A1 (en) 2017-08-22 2019-02-28 Rubius Therapeutics, Inc. Lipid nanoparticle methods and compositions for producing engineered erythroid cells
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
WO2019133881A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for enginerering erythroid cells

Also Published As

Publication number Publication date
RS62939B1 (sr) 2022-03-31
CN108778298A (zh) 2018-11-09
US10568910B2 (en) 2020-02-25
SG10202007639SA (en) 2020-09-29
LT3402491T (lt) 2022-02-25
PL3402491T3 (pl) 2022-04-19
CA3009063A1 (en) 2017-07-20
IL260010A (en) 2018-07-31
ES2907695T3 (es) 2022-04-26
SG11201805253SA (en) 2018-07-30
HUE057660T2 (hu) 2022-06-28
SG11201805442XA (en) 2018-07-30
EP3402491A1 (en) 2018-11-21
US20190083540A1 (en) 2019-03-21
JP2019501655A (ja) 2019-01-24
US20180193385A1 (en) 2018-07-12
JP2019501654A (ja) 2019-01-24
US20200129556A1 (en) 2020-04-30
AU2017207736A1 (en) 2018-07-12
WO2017123644A1 (en) 2017-07-20
US10716811B2 (en) 2020-07-21
US20200016209A1 (en) 2020-01-16
US10456421B2 (en) 2019-10-29
EP3402492A1 (en) 2018-11-21
JP2021112216A (ja) 2021-08-05
US20180187155A1 (en) 2018-07-05
IL259991A (en) 2018-07-31
WO2017123646A1 (en) 2017-07-20
EP3402492B1 (en) 2022-11-16
HK1259079A1 (zh) 2019-11-22
DK3402491T3 (da) 2022-02-14
US20220072048A1 (en) 2022-03-10
JP7093302B2 (ja) 2022-06-29
HRP20220147T1 (hr) 2022-04-15
US10517897B1 (en) 2019-12-31
KR20180095098A (ko) 2018-08-24
SG10201913837TA (en) 2020-03-30
MX2018008514A (es) 2019-05-09
US20180085402A1 (en) 2018-03-29
SI3402491T1 (sl) 2022-05-31
MX2018008515A (es) 2019-05-09
EP3402491B1 (en) 2021-12-22
CA3010510A1 (en) 2017-07-20
JP2022171843A (ja) 2022-11-11
CN108697733A (zh) 2018-10-23
AU2017207738A1 (en) 2018-07-12
US20230293588A1 (en) 2023-09-21
EP4019026A1 (en) 2022-06-29
PT3402491T (pt) 2022-03-03
KR20180095713A (ko) 2018-08-27
JP2021078519A (ja) 2021-05-27
CN115969987A (zh) 2023-04-18
BR112018013728A2 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
BR112018013853A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
CO2017010618A2 (es) Anticuerpos contra icos
BR112019010943A2 (pt) métodos para o tratamento do câncer compreendendo agentes de ligação a tigit
BR112018013074A2 (pt) terapias de célula efetora imune com eficácia real-çada
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112019004733A2 (pt) métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
BR112017006664A2 (pt) terapias de combinação
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
PH12019501010A1 (en) Arginase inhibitor combination therapies
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MA40364A (fr) Polythérapie pour le traitement du cancer
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
BR112017003334A8 (pt) Variantes de desintegrina e usos farmacêuticos destas

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: RUBIUS THERAPEUTICS, INC. (US)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements